Ostalo
TUMORS IN KIDNEY DONORS – ETHIC DILEMMA IN TRANSPLANTATION MEDICINE
MARKO BANIĆ
; Sveučilište u Zagrebu, Medicinski fakultet, Klinički bolnički centar Zagreb, Zavod za nefrologiju, arterijsku hipertenziju, dijalizu i transplantaciju, Zagreb, Hrvatska
ALAN HORVAT
; Sveučilište u Zagrebu, Medicinski fakultet, Klinički bolnički centar Zagreb, Zavod za nefrologiju, arterijsku hipertenziju, dijalizu i transplantaciju, Zagreb, Hrvatska
LEA KATALINIĆ
; Klinički bolnički centar Zagreb, Klinika za urologiju, Zagreb, Hrvatska
VESNA FURIĆ-ČUNKO
; Klinički bolnički centar Zagreb, Klinika za urologiju, Zagreb, Hrvatska
IVANA JURIĆ
; Klinički bolnički centar Zagreb, Klinika za urologiju, Zagreb, Hrvatska
TVRTKO HUDOLIN
; Sveučilište u Zagrebu, Medicinski fakultet, Klinički bolnički centar Zagreb, Zavod za nefrologiju, arterijsku hipertenziju, dijalizu i transplantaciju, Zagreb, Hrvatska
ŽELJKO KAŠTELAN
; Sveučilište u Zagrebu, Medicinski fakultet, Klinički bolnički centar Zagreb, Zavod za nefrologiju, arterijsku hipertenziju, dijalizu i transplantaciju, Zagreb, Hrvatska
NIKOLINA BAŠIĆ-JUKIĆ
orcid.org/0000-0002-0221-2758
; Sveučilište u Zagrebu, Medicinski fakultet, Klinički bolnički centar Zagreb, Zavod za nefrologiju, arterijsku hipertenziju, dijalizu i transplantaciju i Klinika za urologiju, Zagreb, Hrvatska
Sažetak
It is known that the incidence of malignant diseases is increased 3 to 4 times when the population of solid organs recipients is observed. Apart from the tumours developed from one's own tissues, tumour recipients may develop a malignant tumour related to the donated organ. The chance of developing such a disease is far smaller than the one of developing a malignant disease originating from one's own tissues but the chance is not non-existant. It is necessary to examine whether such a risk is worth taking and whether the donated organ should be explanted in the case of discovering a malignancy in donor. Another problem is the fact that a portion of such tumours is discovered not before the deceased donor's obduction. Acorrding to researches outside of Croatia, 0,01-0,05% of kidney recipients develop a malignancy transmitted from the donor. In Croatian terms, that would be equivalent to 0,02-0,1 persons per year. Increased risk groups would be donors over the age of 45 and donors with a history of malignant disease. There are no clear guidelines developed yet but there are some widely-accepted procedures in certain situations. Each patient must be individually evaluated and cost-benefit analysis must be taken into account. Four cases occured in the Hospital University Center Zagreb when the autopsy discovered a malignancy in kidney donors.
Ključne riječi
HIV; kidney transplantation; outcome; kidney transplantation; kidney donor; tumour; kidney recipient; ethics
Hrčak ID:
230108
URI
Datum izdavanja:
5.12.2019.
Posjeta: 1.276 *